Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease

Allergic rhinitis is a condition which affects over 15% of the population in the United Kingdom. The pathological process involves two stages: nasal inflammation, and the development of nasal airway hyperresponsiveness (AHR) to allergen and a number of other stimuli. This results in the amplificatio...

Full description

Bibliographic Details
Main Authors: P. J. Turner, J. C. Foreman
Format: Article
Language:English
Published: Hindawi Limited 1999-01-01
Series:Mediators of Inflammation
Subjects:
Online Access:http://dx.doi.org/10.1080/09629359990469
id doaj-d7f678af7d2942a1b999bf2b7350bf8f
record_format Article
spelling doaj-d7f678af7d2942a1b999bf2b7350bf8f2020-11-24T20:59:59ZengHindawi LimitedMediators of Inflammation0962-93511466-18611999-01-018313314610.1080/09629359990469Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway DiseaseP. J. Turner0J. C. Foreman1Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UKDepartment of Pharmacology, University College London, Gower Street, London WC1E 6BT, UKAllergic rhinitis is a condition which affects over 15% of the population in the United Kingdom. The pathological process involves two stages: nasal inflammation, and the development of nasal airway hyperresponsiveness (AHR) to allergen and a number of other stimuli. This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state. A number of different hypotheses have been proposed to explain the underlying mechanism of AHR, including a role for eosinophil-derived proteins, free radicals and neuropeptides. While there may be a number of independent pathways which can result in AHR, evidence obtained from both animal models and in vivo experiments in humans indicate that some mediators may interact with one another, resulting in AHR. Further research into these interactions may open new avenues for the pharmacological treatment of chronic allergic rhinitis, and possibly other allergic airway diseases.http://dx.doi.org/10.1080/09629359990469Human nasal airwayHyperresponsiveness EosinophilsBradykininNeuropeptidesNitric oxide.
collection DOAJ
language English
format Article
sources DOAJ
author P. J. Turner
J. C. Foreman
spellingShingle P. J. Turner
J. C. Foreman
Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
Mediators of Inflammation
Human nasal airway
Hyperresponsiveness
Eosinophils
Bradykinin
Neuropeptides
Nitric oxide.
author_facet P. J. Turner
J. C. Foreman
author_sort P. J. Turner
title Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
title_short Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
title_full Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
title_fullStr Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
title_full_unstemmed Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
title_sort hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease
publisher Hindawi Limited
series Mediators of Inflammation
issn 0962-9351
1466-1861
publishDate 1999-01-01
description Allergic rhinitis is a condition which affects over 15% of the population in the United Kingdom. The pathological process involves two stages: nasal inflammation, and the development of nasal airway hyperresponsiveness (AHR) to allergen and a number of other stimuli. This results in the amplification of any subsequent allergic reaction, contributing to the chronic allergic state. A number of different hypotheses have been proposed to explain the underlying mechanism of AHR, including a role for eosinophil-derived proteins, free radicals and neuropeptides. While there may be a number of independent pathways which can result in AHR, evidence obtained from both animal models and in vivo experiments in humans indicate that some mediators may interact with one another, resulting in AHR. Further research into these interactions may open new avenues for the pharmacological treatment of chronic allergic rhinitis, and possibly other allergic airway diseases.
topic Human nasal airway
Hyperresponsiveness
Eosinophils
Bradykinin
Neuropeptides
Nitric oxide.
url http://dx.doi.org/10.1080/09629359990469
work_keys_str_mv AT pjturner hyperresponsivenessinthehumannasalairwaynewtargetsforthetreatmentofallergicairwaydisease
AT jcforeman hyperresponsivenessinthehumannasalairwaynewtargetsforthetreatmentofallergicairwaydisease
_version_ 1716780753943003136